Nature Podcast

The Nature Podcast brings you the best stories from the world of science each week. We cover everything from astronomy to zoology, highlighting the most exciting research from each issue of Nature journal. We meet the scientists behind the results and provide in-depth analysis from Nature's journalists and editors. For complete access to the original papers featured in the Nature Podcast, subscribe to Nature.

http://www.nature.com/nature/podcast

subscribe
share





Coronapod: Ivermectin, what the science says


Ivermectin is a cheap, widely available, anti-parasitic drug that has been proposed by many as a possible treatment for COVID-19. Dozens of trials have been started, but results have been far from clear, with inconsistent results further confused by high profile paper retractions. Nonetheless many countries have recommended the use of Ivermectin, despite WHO advice to the contrary.


Now a group of researchers have found suspect data in another influential paper which claimed a Ivermectin caused a 90% reduction in fatality. The paper, published at the end of 2020, has since been withdrawn pending investigation. In this episode of Coronapod we ask what this might mean for Ivermectin, and what's next for the controversial drug.



Correction: at 2:53 when discussing two discredited studies, we mistakenly say that the papers say "both drugs worked really well". In fact, this retracted study from the Lancet claimed that the drug hydroxychloroquine caused harm. We apologise for any confusion. More information on the scandal surrounding these papers can be found here.


News:Flawed ivermectin preprint highlights challenges of COVID drug studies


News: Latin America’s embrace of an unproven COVID treatment is hindering drug trials


Coronapod: The Surgisphere scandal that rocked coronavirus drug research


Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

 

See acast.com/privacy for privacy and opt-out information.


share







 2021-08-06  12m